Literature DB >> 25891862

Jumping translocations, a novel finding in chronic lymphocytic leukaemia.

Cecelia R Miller1,2, Deborah Stephens1,3, Amy S Ruppert1, Frederick Racke4, Andrew McFaddin3, Heather Breidenbach4, Huey-Jen Lin2, Kathy Waller2, Tammy Bannerman2, Jeffrey A Jones1,3, Jennifer A Woyach1,3, Leslie A Andritsos1,3, Kami Maddocks1,3, Weiqiang Zhao4, Gerard Lozanski4, Joseph M Flynn1,3, Michael Grever1,3, John C Byrd1,3,5, Nyla A Heerema4.   

Abstract

A jumping translocation (JT) is a rare cytogenetic aberration that can occur in haematological malignancy. It involves the translocation of the same fragment of donor chromosome onto two or more recipient chromosomes, typically in different cells. In this study, we describe the first series of chronic lymphocytic leukaemia (CLL) patients with JTs reported to date. Following a review of 878 CLL patient karyotypes, we identified 26 patients (3%) with 97 JTs. The most commonly occurring breakpoint in these translocations was 17p11.2. Loss of TP53 was identified prior to or at the same time as JT in 23 of 26 patients (88%). All patients eventually developed a complex karyotype. All but one patient has required treatment for CLL, with estimated median time to treatment of 11·5 months. This study establishes JTs as a recurrent abnormality found in CLL patients with aggressive disease. JTs contribute to complex karyotypes and, in many cases, are involved in chromosomal rearrangements that result in loss of the tumour suppressor gene TP53.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  TP53; cancer cytogenetics; chromosomal rearrangement; chronic lymphocytic leukaemia; complex karyotype

Mesh:

Year:  2015        PMID: 25891862      PMCID: PMC4490025          DOI: 10.1111/bjh.13422

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  33 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

3.  Jumping translocation of 17q11 approximately qter and 3q25 approximately q28 duplication in a variant Philadelphia t(9;14;22)(q34;q32;q11) in a childhood chronic myelogenous leukemia.

Authors:  Irén Haltrich; Maria Kost-Alimova; Gábor Kovács; Gergely Kriván; Júlia Tamáska; George Klein; György Fekete; Stefan Imreh
Journal:  Cancer Genet Cytogenet       Date:  2006-01-01

4.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Authors:  John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

5.  Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.

Authors:  Stephanie R Fink; Stephanie A Smoley; Kimberly J Stockero; Sarah F Paternoster; Erik C Thorland; Daniel L Van Dyke; Tait D Shanafelt; Clive S Zent; Timothy G Call; Neil E Kay; Gordon W Dewald
Journal:  Cancer Genet Cytogenet       Date:  2006-06

Review 6.  Richter's transformation in chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Susan O'Brien
Journal:  Oncology (Williston Park)       Date:  2012-12       Impact factor: 2.990

7.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.

Authors:  Frank Dicker; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Schoch
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

8.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

Authors:  Michael R Grever; David M Lucas; Gordon W Dewald; Donna S Neuberg; John C Reed; Shinichi Kitada; Ian W Flinn; Martin S Tallman; Frederick R Appelbaum; Richard A Larson; Elisabeth Paietta; Diane F Jelinek; John G Gribben; John C Byrd
Journal:  J Clin Oncol       Date:  2007-02-05       Impact factor: 44.544

9.  Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Joshua Epstein; Donald J Johann; Charles M Swanson; Janet L Lukacs; Marian Johnson; Regina Binz; Angela Boast; Gael Sammartino; Saad Usmani; Maurizio Zangari; Sarah Waheed; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

Review 10.  Jumping translocations.

Authors:  Roland Berger; Olivier A Bernard
Journal:  Genes Chromosomes Cancer       Date:  2007-08       Impact factor: 5.006

View more
  2 in total

1.  A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q- syndrome.

Authors:  Walter Arancio; Swonild Ilenia Genovese; Lucia Bongiovanni; Claudio Tripodo
Journal:  Oncoscience       Date:  2015-11-11

2.  Molecular cytogenetic pilot study on pleomorphic adenomas of salivary glands.

Authors:  Jovanna Thielker; Anja Weise; Moneeb A K Othman; Isabel M Carreria; Joana B Melo; Ferdinand Von Eggeling; Orlando Guntinas-Lichius; Monika Ziegler; Thomas Liehr
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.